Share:
ProPath, the largest fully physician-owned pathology practice in the United States, today announced that Julia A. Bridge, M.D., a board-certified pathologist and geneticist with an extensive medical career and expertise in solid tumor molecular testing, has joined the ProPath team.
Dr. Bridge, who recently directed the Molecular Pathology Research Division at the Translational Genomics Research Institute in Phoenix, AZ, will be directing ProPath s fluorescence in situ hybridization (FISH) and cytogenetics team. She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPath s molecular pathology team. We are thrilled to have Dr. Bridge join our team, said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath. She has a rare combination of expertise in both anatomic pathology and cytogenetics that make her an expert with an international consultative practice. Her ability to interpret microscopic morphology in concert with her unsurpass
Easy Health Options®
A Chinese herb may hold the key to fighting pancreatic cancer
A diagnosis of pancreatic cancer is pretty grim. In fact, the five-year survival rate is less than 10 percent. But, thankfully, medical researchers are busy exploring new avenues of treatment for the deadly disease. And one team has identified a compound from a plant commonly used in Traditional Chinese Medicine that may be able to help…
The death of Jeopardy! host Alex Trebek in November once again shone a spotlight on one of the deadliest of all cancers, pancreatic cancer. Mr. Trebek was diagnosed with stage 4 pancreatic cancer in March 2019 and managed to extend the grim 8-month prognosis given to most pancreatic cancer patients receiving good treatment for the disease.
Open Innovation R&D has evolved from a private company effort to a collaboration
between private, public and academic partners. Sarah Harney | December 2004
Seventy-five years ago, at the dawn of the Great Depression, the owners of the Columbian Rope Co. made a daring move. While other manufacturing companies were cutting back, Columbian pressed forward with plans to create a New Products Research Laboratory adjacent to the rope company s large factory in upstate New York.
The young scientist Columbian selected to run the lab was my grandfather, Edgar Johnson, then a chemistry professor at Cornell University. It was a classic example of private industry luring a significant talent out of academia. In 1930, Johnson left the cozy intellectual sophistication of Ithaca and moved his family including my concert-pianist grandmother forty miles north to the factory town of Auburn.
TGen Leverages phoenixNAP’s Hardware-as-a-Service Powered by Intel® to Empower COVID-19 Research
Share Article
Empowering COVID-19 Research with Cutting-Edge Tech We got a more streamlined, powerful infrastructure that will give us enough power and memory, while at the same time providing us with a great degree of flexibility as our research expands, said Glen Otero, VP Scientific Computing, TGen. PHOENIX (PRWEB) December 23, 2020 phoenixNAP®, a global IT services provider offering security-focused cloud infrastructure, dedicated servers, colocation, and specialized Infrastructure-as-a-Service technology solutions, announced a case study detailing its collaboration with Intel® on building an IT platform for a COVID-19 project by Translational Genomics Research Institute (TGen), an affiliate of City of Hope.